ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Favorable Prognosis Stage I and II

Prajnan Das*, Andrea Ng, Louis S. Constine, David C. Hodgson, Nancy P. Mendenhall, David Eric Morris, Michael J. Yunes, Allen R. Chauvenet, Melissa M. Hudson, Jane N. Winter

*Corresponding author for this work

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The treatment for favorable-prognosis stage I and II Hodgkin's lymphoma has evolved over the past several years. Studies have attempted to reduce long-term treatment-related side effects, such as second malignancies and cardiac toxicity, through reduced chemotherapy or reduced radiotherapy. Randomized trials have compared radiation therapy alone with combined-modality therapy (chemotherapy followed by involved-field radiotherapy). Recent and ongoing trials have evaluated the optimal regimen and number of cycles of chemotherapy and the optimal radiotherapy dose and field size as part of combined-modality therapy, as well as the elimination of radiation therapy. Combined-modality therapy represents the current standard of care for most patients with favorable-prognosis early-stage Hodgkin's lymphoma. Chemotherapy alone could also be an option for selected patients who are at low risk for relapse and high risk for late effects from radiotherapy. This article reviews recent and ongoing studies on treatment for favorable-prognosis early stage Hodgkin's lymphoma. Representative clinical cases are presented, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

Original languageEnglish (US)
Pages (from-to)1054-1066
Number of pages13
JournalJournal of the American College of Radiology
Volume5
Issue number10
DOIs
StatePublished - Oct 2008

Keywords

  • Hodgkin's lymphoma
  • chemotherapy
  • involved field
  • late toxicity
  • radiation therapy
  • second malignancy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'ACR Appropriateness Criteria<sup>®</sup> on Hodgkin's Lymphoma-Favorable Prognosis Stage I and II'. Together they form a unique fingerprint.

Cite this